Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with Alzheimer’s disease and as an adjunctive treatment for Major Depressive Disorder, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
Corporate
BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com
Investor
BioXcel Therapeutics
Brennan Doyle
T: 475-355-8462
Bdoyle@bioxceltherapeutics.com
Media
Russo Partners
David Schull
T: 858-717-2310
David.schull@russopartnersllc.com
Scott Stachowiak
T: 646-942-5630
Scott.stachowiak@russopartnersllc.com
Transfer Agent
American Stock Transfer and Trust
Auditor
Ernst & Young LLP
Legal Counsel
Latham & Watkins LLP
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Stock Chart
Featured News
Events
SEC Filings
Filing date | Form | Description | Filing Group |
---|---|---|---|
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
|
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
|
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
|
424B5 | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
Registration Statements
|
|
RW | Withdrawal of registration statement filed under the Securities Act |
Other
|
Data Provided by Refinitiv. Minimum 15 minutes delayed.